๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Intrahepatic Cholangiocarcinoma (Icc)
Clinical trial register · China

Intrahepatic Cholangiocarcinoma (Icc) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 6 Shanghai 5 Beijing 4 Wuhan 3 Tianjin 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou6 Shanghai5 Beijing4 Wuhan3 Tianjin3
All 22 locations
Target enrolment
to

Intrahepatic Cholangiocarcinoma (Icc) trials in China

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
NCT07768085Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
Shengjing Hospital
Not applicable
40,000
Shenyang
2026-08-17
Not yet open
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
NCT07691515Intrahepatic Cholangiocarcinoma (Icc)
Zhejiang Cancer Hospital
Phase 3
140
Guangzhou, Jiangmen, Wuhan, Changsha, Ganzhou, Nanchang, Qingdao, Chengdu
2026-07
Recruiting
Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
NCT07760038Intrahepatic Cholangiocarcinoma (Icc), Liver Injury
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
30
Hangzhou
2026-06-01
Active, closed
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
NCT07646717Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-02-24
Not yet open
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
NCT07353827Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy
Sun Yat-sen University
Phase 2
36
Guangzhou
2026-02-01
Not yet open
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
NCT07328919Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Active, closed
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
NCT07658586Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc)
Guangxi Medical University
Observational
600
Nanning
2025-12-01
Not yet open
A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST
NCT07208526Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST, GOLP Regimen
Shanghai Zhongshan Hospital
Not applicable
270
Shanghai
2025-12-01
Recruiting
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT07070700Intrahepatic Cholangiocarcinoma (Icc)
Fudan University
Phase 2
56
Shanghai
2025-08-20
Recruiting
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
NCT07063888Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin, Lymph Node Involvement
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
66
Beijing
2025-05-16
Recruiting
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study
NCT07640048Intrahepatic Cholangiocarcinoma (Icc)
Peking Union Medical College Hospital
Observational
90
Beijing
2025-05-04
Recruiting
A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
NCT06925516Intrahepatic Cholangiocarcinoma (Icc)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
38
Guangzhou
2025-04-25
Recruiting
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
NCT06721286Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
70
Tianjin
2024-11-12
Not yet open
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ยฑ Lenvatinib As First-line Treatment for Advanced ICC
NCT06648525Intrahepatic Cholangiocarcinoma (Icc)
Harbin Medical University
Phase 2
68
Harbin
2024-10
Recruiting
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
NCT06852287Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2024-09-01
Recruiting
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
NCT07101237Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), Primary Liver Cancer
Peking Union Medical College Hospital
Observational
308
Beijing
2024-08-01
Recruiting
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270Intrahepatic Cholangiocarcinoma (ICC)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Recruiting
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
NCT07176962Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma
Yingbin Liu, MD, PhD, FACS
Observational
1,800
Shanghai
2020-01-01
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/intrahepatic-cholangiocarcinoma-icc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition Intrahepatic Cholangiocarcinoma (Icc).

How many Intrahepatic Cholangiocarcinoma (Icc) trials are recruiting in China?

11 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Intrahepatic Cholangiocarcinoma (Icc)), 21 studies
PhaseStudiesRecruitingShare
Phase 211752.4%
Observational4319%
Not applicable3114.3%
Phase 3209.5%
Phase 1/2104.8%

Most active sponsors

Lead sponsors with the most studies (Intrahepatic Cholangiocarcinoma (Icc))
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital32
Peking Union Medical College Hospital22
Shanghai Zhongshan Hospital20
Beijing InnoCare Pharma Tech Co., Ltd.11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Fudan University11
Guangxi Medical University10
Harbin Medical University10
Second Affiliated Hospital, Zhejiang University, School of Medicine11
Shanghai 6th People's Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.